Metrika članka

  • citati u SCindeksu: 0
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[=>]
  • posete u poslednjih 30 dana:4
  • preuzimanja u poslednjih 30 dana:1
članak: 6 od 293  
Back povratak na rezultate
Vojnosanitetski pregled
2019, vol. 76, br. 5, str. 547-551
jezik rada: engleski
vrsta rada: prikaz slučaja
doi:10.2298/VSP170424107R

Creative Commons License 4.0
Svetloćelijski/endometrioidni karcinom jajnika udružen sa endometriozom u istom jajniku
aUniverzitet u Beogradu, Medicinski fakultet, GAK 'Narodni front'
bClinic of Gynecology and Obstetrics "Narodni Front", Belgrade + University of Belgrade, Faculty of Medicine, Belgrade

e-adresa: rudic.biljic@gmail.com

Sažetak

Uvod. Endometrioza jajnika je identifikovana kao faktor rizika od nastanka karcinoma jajnika udruženog sa endometriozom. Prikazali smo bolesnicu sa istovremenom pojavom svetloćelijskog/endometrioidnog tipa karcinoma jajnika i endometrioze u istom jajniku. Prikaz bolesnika. Bolesnica, stara 47 godina, podvrgnuta je operativnom zahvatu zbog endometriotične ciste na desnom jajniku. Urađena je histerektomija sa obostranom adneksektomijom, limfadenektomija regije desnog slabinskog mišića, omentektomija i višestruke biopsije peritoneuma. Posle operacije primenjena je hemioterapija u toku šest ciklusa po protokolu Taxol-CBDCA. Nakon hiruškog zahvata i sprovedenog lečenja hemioterapijom urađen je kontrolni CT abdomena i male karlice i kod bolesnice nisu nađeni znakovi recidiva bolesti. Šest meseci posle završenog lečenja bolesnica se dobro osećala i nije imala recidiv bolesti. Zaključak. Svetloćelijski i endometrioidni podtip karcinoma jajnika imaju dobru prognozu ako se otkriju i leče u ranom stadijumu bolesti. Kod prikazane bolesnice karcinom je otkriven u prvom stadijumu i uspešno je lečen kombinovanom terapijom tj. hiruški i hemioterapijom.

Ključne reči

adenokarcinom svetlih ćelija; dijagnoza; endometrioza; jajnik; neoplazme; lečenje; ishod

Reference

Borrelli, G.M., Abrão, M.S., Taube, E.T., Darb-Esfahani, S., Köhler, C., Chiantera, V., Mechsner, S. (2016) (Partial) Loss of BAF250a (ARID1A) in rectovaginal deep-infiltrating endometriosis, endometriomas and involved pelvic sentinel lymph nodes. Molecular Human Reproduction, 22(5): 329-337
Burghaus, S., Häberle, L., Schrauder, M.G., Heusinger, K., Thiel, F.C., Hein, A., Wachter, D., Strehl, J., Hartmann, A., Ekici, A.B., Renner, S.P., Beckmann, M.W., Fasching, P.A. (2015) Endometriosis as a risk factor for ovarian or endometrial cancer: Results of a hospital-based case-control study. BMC Cancer, 15(1): 751-751
Forte, A., Cipollaro, M., Galderisi, U. (2014) Genetic, epigenetic and stem cell alterations in endometriosis: New insights and potential therapeutic perspectives. Clinical Science, 126(2): 123-138
Helder-Woolderink, J.M., Blok, E.A., Vasen, H.F.A., Hollema, H., Mourits, M.J., de Bock, G.H. (2016) Ovarian cancer in Lynch syndrome; a systematic review. European Journal of Cancer, 55: 65-73
Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., Forman, D. (2011) Global cancer statistics. CA: A Cancer Journal for Clinicians, 61(2): 69-90
Lyttle, B., Bernardi, L., Pavone, M.E. (2014) Ovarian cancer in endometriosis: Clinical and molecular aspects. Minerva Ginekol, 66(2): 15564-15564
Ma, X., Hui, Y., Lin, L., Wu, Y., Zhang, X., Qin, X. (2016) Possible relevance of tumor-related genes mutation to malignant transformation of endometriosis. Eur J Gynaecol Oncol, 37(1): 8994-8994
Noli, S., Cipriani, S., Scarfone, G., Villa, A., Grossi, E., Monti, E., Vercellini, P., Parazzini, F. (2013) Long Term Survival of Ovarian Endometriosis Associated Clear Cell and Endometrioid Ovarian Cancers. International Journal of Gynecological Cancer, 23(2): 244-248
Pavone, M.E., Lyttle, B.M. (2015) Endometriosis and ovarian cancer: Links, risks, and challenges faced. International Journal of Women's Health, 7: 663-663
Rechsteiner, M., Zimmermann, A., Wild, P.J., Caduff, R., von Teichman, A., Fink, D., Moch, H., Noske, A. (2013) TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type. Experimental and Molecular Pathology, 95(2): 235-241
Suryawanshi, S., Huang, X., Elishaev, E., Budiu, R.A., Zhang, L., Kim, S., Donnellan, N., Mantia-Smaldone, G., Ma, T., Tseng, G., Lee, T., Mansuria, S., Edwards, R.P., Vlad, A.M. (2014) Complement Pathway Is Frequently Altered in Endometriosis and Endometriosis-Associated Ovarian Cancer. Clinical Cancer Research, 20(23): 6163-6174
Teixeira, N., Mourits, M.J.E., Vos, J.R., Kolk, D.V.der M., Jansen, L., Oosterwijk, J.C., Bock, G.D.H. (2015) Ovarian cancer in BRCA1/2 mutation carriers: The impact of mutation position and family history on the cancer risk. Maturitas, 82(2): 197-202
Wang, S., Qiu, L., Lang, J.H., Shen, K., Yang, J.X., Huang, H.F., Pan, L.Y., Wu, M. (2013) Clinical analysis of ovarian epithelial carcinoma with coexisting pelvic endometriosis. American Journal of Obstetrics and Gynecology, 208(5): 413.e1-413.e5
Worley, M.J., Liu, S., Hua, Y., Kwok, J.S.S., Samuel, A., Hou, L., Shoni, M., Lu, S., Sandberg, E.M., Keryan, A., Wu, D., Ng, S., Kuo, W.P., Parra-Herran, C.E., Tsui, S.K.W., Welch, W. (2015) Molecular changes in endometriosis-associated ovarian clear cell carcinoma. European Journal of Cancer, 51(13): 1831-1842